CP
BCYC

Castleview Partners’s Bicycle Therapeutics BCYC Stock Holding History

Castleview Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$8K Buy
+253
New +$7.64K ﹤0.01% 732

Other funds holding BCYC

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Castleview Partners's BCYC Position: Q2 2021 in Review

Castleview Partners opened a new position in Bicycle Therapeutics (BCYC) in Q2 2021: 253 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #732 among its holdings.

54 funds tracked by Wall St. Rank hold BCYC as of Q2 2021.

  • Castleview Partners held 253 shares of Bicycle Therapeutics worth $8K as of Q2 2021.
  • Bicycle Therapeutics was a new Castleview Partners position in Q2 2021.
  • Bicycle Therapeutics made up ﹤0.01% of Castleview Partners's portfolio in Q2 2021, its #732 holding.
  • 54 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2021.

Based on Castleview Partners's 13F filing for Q2 2021, filed 17 Aug 2021.